RE-BVS – Piemonte Repository

Sfoglia per AUTORE
IACOVELLI R
Collezione ASL Asti

Items : 7

2014P Overall survival (OS) results in phase II trial of cabozantinib (CABO) plus durvalumab (DURVA) in patients with urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy (ARCADIA) in Annals of Oncology

2024
ASL Asti

Giannatempo P; Polymeropoulos A; Stellato M; Ambrosini P; Gusmaroli E; Cavalli C; Guadalupi V; Claps M; Raggi D; Rametta A; Ortega C; Tucci M; Buti S; Pipitone S; Iacovelli R; Calareso G; Alessi A; Procopio G; Miceli R; Necchi A;

1981P Cabozantinib plus durvalumab in patients with advanced and chemotherapy-treated urothelial carcinoma (UC) and variant histology (VH): An open-label, phase II, single-arm proof-of-concept trial: ARCADIA study. Subgroup analysis for bone metastasis in Annals of Oncology

2024
ASL Asti

Stellato M; Giannatempo P; Polymeropoulos A; Guadalupi V; Claps M; Ambrosini P; Raggi D; Rametta A; Cavalli C; Gusmaroli E; Ortega C; Tucci M; Buti S; Pipitone S; Iacovelli R; Calareso G; Alessi A; Procopio G; Miceli R; Necchi A;

Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study. in Journal for immunotherapy of cancer / J Immunother Cancer. 2022 Jan;10(1):e003697. doi: 10.1136/jitc-2021-003697.

2022
ASL Asti

Zucali PA; Lin CC; Carthon BC; Bauer TM; Tucci M; Italiano A; Iacovelli R; Su WC; Massard C; Saleh M; Daniele G; Greystoke A; Gutierrez M; Pant S; Shen YC; Perrino M; Meng R; Abbadessa G; Lee H; Dong Y; Chiron M; Wang R; Loumagne L; Lépine L; de Bono J;

MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma. in Journal of clinical pathology / J Clin Pathol. 2022 Jan;75(1):39-44. doi: 10.1136/jclinpath-2020-207089. Epub 2020 Nov 3.

2022
ASL Asti

Brunelli M; Tafuri A; Cima L; Cerruto MA; Milella M; Zivi A; Buti S; Bersanelli M; Fornarini G; Vellone VG; Rebuzzi SE; Procopio G; Verzoni E; Bracarda S; Sabbatini R; Baldessari C; Eccher A; Passalacqua R; Perrucci B; Giganti MO; Donini M; Panni S; Tucci M; Prati V; Ortega C; Caliò A; Alongi F; Munari E; Pappagallo G; et alii...

Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. in Journal of personalized medicine / J Pers Med. 2022 Apr 30;12(5):727. doi: 10.3390/jpm12050727.

2022
ASL Asti
AOU Novara

Fassan M; Sbaraglia M; Galuppini F; Aberasturi Plata Y; Zito-Marino F; Franco R; Rizzo M; Massari F; Cossarizza A; Bollito E; Salvioni R; Conti G; Lapini A; Colombo P; Patriarca C; Pierconti F; Basso U; Maruzzo M; Munari E; Atzori F; Montagnani I; Gobbo S; Umari P; Mosca A; Iacovelli R; Pappagallo G; Alongi F; Eccher A; Ortega C; et alii...

Targeting CD38 and PD-1 with isatuximab (Isa) plus cemiplimab (Cemi) in patients (pts) with advanced malignancies: Results from a Phase 1/2 open-label, multicenter study in Cancer Research

2021
ASL Asti

Lin C-C; Zucali P; Carthon B; Bauer TM; Tucci M; Italiano A; Iacovelli R; Su W-C; Massard C; Saleh M; Daniele G; Greystoke A; Gutierrez M; Pant S; Shen Y-C; Perrino M; Meng R; Abbadessa G; Lee H; Dong Y; Chiron M; Wang R; Loumagne L; De Bono J;

The prognostic value of pain in castration-sensitive prostate cancer. in Prostate cancer and prostatic diseases / Prostate Cancer Prostatic Dis. 2020 Dec;23(4):654-660. doi: 10.1038/s41391-020-0255-x. Epub 2020 Jul

2020
ASL Asti

Iacovelli R; Ciccarese C; Caffo O; De Giorgi U; Tucci M; Mosillo C; Bimbatti D; Pierantoni F; Maines F; Casadei C; Buttigliero C; Milella M; Tortora G;